Three stocks which you have missed – OPXA, CEP, REV

Northern, WI 02/06/2013 (wallstreetpr) – It was a day for stocks like Opexa therapeutics, Constellation energy partners and Revlon inc which gained most on the backdrop of news and positive sentiment.

  1. Opexa Therapeutics Inc (NASDAQ:OPXA): OPXA (Opexa Therapeutics Inc.) is a bio pharmaceutical company specialized in developing personalized cellular therapies for curing potential illness. The share of the company went up by as much as 211% during intraday and settled at $3.15 per share during closing with an increase of 160.33%. It was one of the most active stocks after it announced its agreement with Merck Serono, for development and marketing of Tcelna, a Tcell therapy to treat multiple sclerosis. Share price reached a new 52 week high. Company is set for its Q4 earnings call on February 21st 2013.
  2. Constellation Energy Partners LLC (NYSEARCA:CEP): Constellation Energy Partners LLC went up by 30.77% after news came in that the company is in talks for a acquisition, development and production of onshore oil and gas in United States. Earlier company had entered into an agreement to sell its Robinson’s Bend field to a subsidiary of Castleton commodities International LLC Which is expected to be completed by Q1, 2013.
  3. REV: (NYSE:REV): Revlon Inc shares closed at $18.13 a share on Tuesday with an increase of 18.31%. The largest beauty care product company posted a strong increase in sale of its makeup and hair color products. Net income for Q4 rose 28% compared to previous quarter, it also said that the interest rate for $500 Million worth notes was fixed at 5.75% which is due in 2021

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at